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Abstract Post-translational modification of proteins with
ubiquitin plays a central role in regulating numerous
cellular processes. E3 ligases determine the specificity of
ubiquitination by mediating the transfer of ubiquitin to sub-
strate proteins. The family of tripartite motif (TRIM) proteins
make up one of the largest subfamilies of E3 ligases.
Accumulating evidence suggests that dysregulation of TRIM
proteins is associated with a variety of diseases. In this review
we focus on the involvement of TRIM proteins in blood
cancers.
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Introduction
Ubiquitination is a post-translational modification involving
the covalent conjugation of one or more ubiquitin molecules
to a substrate protein. The attachment of ubiquitin to a protein
is important for the regulation of many cellular processes; it
can mark a protein for degradation through the 26S protea-
some, modify interactions with other proteins, alter cellular
localisation or affect activity. The process of ubiquitination
is catalysed by the sequential action of three types of enzymes.
An E1 enzyme activates ubiquitin and transfers it to an E2
conjugating enzyme, E2 enzymes then work in conjunction
with E3 ubiquitin ligases to transfer ubiquitin to a target
protein. It is generally accepted that E3 ligases are responsible
for substrate recognition and therefore confer specificity to the
system (Yau and Rape 2016). Over 600 E3 ligases have been
characterised in humans and are classified into 3 different
classes: homologous to E6-AP carboxyl terminus (HECT),
really interesting new gene (RING) and RING-between-
RING (RBR) (Buetow and Huang 2016). RING proteins are
the largest class of E3 ligases and among them the tripartite
motif (TRIM) family of proteins represent the largest subfam-
ily of RINGs. TRIM proteins are involved in many biological
processes including transcriptional regulation, cell prolifera-
tion and differentiation, intracellular signalling, apoptosis and
immune signalling. Thus, it is not surprising that alterations of
TRIM proteins are associated with a variety of pathologies
including developmental disorders, inflammatory diseases
and cancers. This review will provide an overview of the
TRIM family and discuss alterations in TRIM proteins that
are implicated in blood cancers.
TRIM family overview
TRIM proteins, also referred to as RBBC proteins, are
characterised by the presence of an N-terminal tripartite or
RBBC motif comprised of a RING domain, either one or two
B-boxes (B1 and B2), and a coiled-coil (CC) domain, followed
by a highly variable C-terminal domain (Reymond et al. 2001;
Torok and Etkin 2001). To date, more than 70 TRIM family
members have been identified and these are categorised into 11
subgroups (C-I –C-XI) based on the type of C-terminal domain
present (Short and Cox 2006; Ozato et al. 2008); a number of
TRIMs lacking a RING domain remain unclassified (Fig. 1).
Based on the presence of a RING domain, the majority of
TRIMs are defined as E3 ligases (Meroni and Diez-Roux
2005). However it should be noted that the ability to mediate
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the conjugation of the ubiquitin-like modifications, SUMO and
ISG15, is also attributed to a small number of TRIMs (Zou and
Zhang 2006; Chu and Yang 2011). The RING domain is a
specialised type of zinc finger that confers E3 ligase activity
by binding to an ubiquitin-loaded E2 enzyme and promoting
the transfer of ubiquitin to a target protein. The B-box domains,
in common with the RING domain, are zinc fingers, however,
their structural and functional role is less well defined. It has
been suggested that due to similarities to the RING domain,
they could enhance the E3 ligase activity and even confer E3
ligase activity to RINGless TRIMs, as is the case for TRIM16
(Bell et al. 2012). The coiled-coil domain mediates
oligomerisation, that is homo-dimerisation and potentially
higher order oligomerisation, a process believed to be required
for their function and E3 ligase activity (Esposito et al. 2017).
In addition to homo-oligomerisation, there are increasing re-
ports of hetero-oligomerisation between TRIMs, particularly
among closely related family members. This is thought to in-
crease the diversity of substrate specificity (Napolitano and
Meroni 2012). The variable C-terminal region of TRIM
Fig. 1 Structural classification of tripartite motif (TRIM) family
proteins. The majority of TRIM proteins contain an N-terminal
RING domain, one or two B-box domains (B1, B2) and a
coiled-coil domain (CC) and are classified into 11 subfamilies
(C-I – C-XI) based on a variable C-terminal domain; there is an
additional unclassified group lacking a RING domain. Some
family members lack one or more domain as denoted in
brackets and by a dashed outline. TRIMs included in this review
are in bold. Abbreviations: ACID – acid-rich region, ARF – ADP-
ribosylation factor family domain, BROMO – bromodomain, COS –
cos-box, FIL – filamin-type I G domain, FN3 – fibronectin type III
repeat, MATH – meprin and TRAF-homology domain, NHL – NCL1,
HT2A and LIN41 domain, PHD - PHD domain, PRY – PRY domain,
SPRY – SPRY domain, TM – transmembrane region
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proteins is predominantly responsible for substrate recognition
and cellular localisation (Micale et al. 2012). The most preva-
lent C-terminal is the PRY-SPRY domain found in subfamilies
C-I and C-IV, this domain is common in immune signalling
proteins (James et al. 2007). Other common C-terminal do-
mains include a COS box found in subfamilies C-I, C-II and
C-III and a fibronectin type III (FN3) domain found in subfam-
ilies C-I and C-III.
TRIM proteins in blood cancers
TRIM proteins function in a broad range of cellular processes
and there is accumulating evidence implicating members of
the TRIM family in the development and progression of var-
ious tumour types. A number of TRIM proteins are linked to
the development of blood cancers, through chromosomal
translocations or dysregulated expression, acting as either a
tumour suppressor or oncogene, depending on the cell type.
The involvement of TRIM proteins in the aetiology of blood
cancers is summarised below and in Table 1.
TRIM62
TRIM62 is a member of the largest subfamily of TRIMs, C.IV,
which contain a C-terminal PRY/SPRY domain. TRIM62 has
been reported to act as a putative tumour suppressor in a num-
ber of cancers, including acute myeloid leukaemia (AML).
AML is heterogeneous malignancy characterised by the clonal
proliferation of immature myeloid cells. It is commonly classi-
fied based on cytogenetic and molecular abnormalities
(Vardiman et al. 2009). Quintas-Cardama et al. (2015) evaluat-
ed TRIM62 protein expression in a large cohort of AML pa-
tients at diagnosis. They found that TRIM62 expression was
significantly lower in CD34+ cells from AML patients com-
pared to healthy volunteers and low levels were significantly
associated with a shorter duration of remission and shorter
event-free and overall survival. These effects were particularly
notable among patients defined as having cytogenetically nor-
mal AML (CN-AML). In this subset of patients a number of
molecular aberrations have been found to play an important
role in prognosis, this study found that TRIM62 represents an
additional independent adverse prognostic factor in CN-AML.
While themode of action of TRIM62 has not been defined, low
TRIM62 levels were associated with altered expression of
proteins involved in stem cell homeostasis, cell motility and
adhesion, hypoxia and apoptosis.
TRIM19
TRIM19 is more commonly known as the promyelocytic leu-
kaemia (PML) protein as it was originally identified as part of
a balanced translocation with retinoic acid receptorα (RARα)
that specifically occurs in acute promyelocytic leukaemia
(APL) (de The et al. 1991). It belongs to the C-V subfamily
of TRIM proteins, which lack any obvious domain other than
R-B1-B2-CC domain that is common to all TRIMs. In normal
cells, PML is essential for the formation of distinct nuclear
structures known as PML nuclear bodies (PML-NB). These
are dynamic structures that are triggered in response to various
cellular stresses. PML-NBs are implicated in the regulation of
a wide range of cellular processes including transcriptional
Table 1 Alterations in TRIM
family members in blood cancers TRIM Blood cancer Alteration Suggested effect Reference
TRIM13 CLL Gene Deletion Tumour suppressor Kapanadze et al. 2000
MM Gene Deletion Oncogene Gatt et al. 2013
TRIM19 APL Translocation:RARα Tumour suppressor Chen and Chen 1992
B-ALL Translocation:PAX5 Tumour suppressor Kurahashi et al. 2011
Lymphoma Reduced expression Tumour suppressor Gurrieri et al. 2004
CML Overexpression Oncogene Ito et al. 2008
TRIM24 AML Overexpression Oncogene Gandini et al. 2002
EMS Translocation:FGFR1 Oncogene Jackson et al. 2010
TRIM33 CMML Reduced expression Tumour suppressor Aucagne et al. 2011
B-ALL N/A Oncogene Wang et al. 2015
MM Reduced expression Tumour suppressor Johnston et al. 2017
TRIM62 AML Reduced expression Tumour suppressor Quintas-Cardama et al. 2015
AML, acute myeloid leukaemia; APL acute promyelocytic leukaemia; B-ALLB cell acute lymphocytic leukaemia;
CLL chronic lymphocytic leukaemia; CML chronic myeloid leukaemia; CMML chronic myelomonocytic leukae-
mia; EMS 8p11 myeloproliferative syndrome; FGFR1 fibroblast growth factor receptor 1; N/A not applicable;
PAX5 paired box 5; RARα retinoic acid receptor α
TRIM proteins in blood cancers
regulation, cell cycle control, apoptosis, senescence, DNA
damage response and anti-viral response (Bernardi and
Pandolfi 2007). There are at least 7 protein isoforms of PML
which all share an identical N-terminal TRIM motif and have
varying C-terminals. However, the majority of isoforms con-
tain a nuclear localisation signal and SUMO-interacting motif
(SIM) which is critical for PML-NB formation (Li et al. 2017).
TRIM19 in acute promyelocytic leukaemia
Acute promyelocytic leukaemia (APL) is a distinct subtype of
AML characterised by the accumulation of abnormal
promyelocytes in the bone marrow. In the majority of patients
(>98%), APL is associated with a balanced reciprocal chro-
mosomal translocation, t(15;17), which produces the PML-
RARα fusion protein (de The et al. 1991). RARα is a nuclear
receptor that regulates transcription in a ligand-dependent
manner. When bound to retinoic acid (RA), RARα induces
the expression of genes promoting myeloid differentiation and
conversely in the absence of RA, RARα represses the tran-
scription of target genes. The PML-RARα fusion protein re-
tains the N-terminal multimerisation domain of PML and the
C-terminal DNA and ligand-binding domain of RARα and
acts in a dominant negative manner to disrupt the function
of both proteins (Chen and Chen 1992). Through the forma-
tion of PML-RARα/PML heterodimers, PML-RARα
antagonises the formation of PML-NBs. In addition, PML-
RARα acts as a transcriptional suppressor of RARα function,
thus inducing a block in differentiation of promyelocytes.
Historically, APL conferred a poor prognosis, however, the
introduction of therapies specifically targeting PML-RARα
has dramatically improved outcomes. Two targeted therapies,
all-trans retinoic acid (ATRA) and arsenic trioxide (ATO),
each act on one partner of the PML-RAR fusion protein
(Zhou et al. 2007). ATRA induces dissociation of co-
repressor complexes from the RARα moiety and subsequent-
ly induces proteasome-mediated degradation of PML-RARα.
This promotes differentiation of leukaemic promyelocytes in-
to mature granulocytes. ATO on the other hand binds to PML
and PML-RARα resulting in sumoylation which in turn pro-
motes polyubiquitination and degradation of PML-RARα
(Tomita et al. 2013). There is a high degree of synergy be-
tween these targeted agents and they are commonly incorpo-
rated into APL induction therapies (Abaza et al. 2017;
Platzbecker et al. 2017).
TRIM19 in other haematological malignancies
In addition to its role in APL, PML exhibits dysregulated
expression in other haematopoietic malignancies. PML has
been found as a translocation partner with the transcription
factor paired box 5 (PAX5) [t(9;15)] in some cases of B-cell
acute lymphocytic leukaemia (B-ALL). Similar to PML-
RARα, the PAX-PML fusion protein acts in a dominant neg-
ative manner to inhibit PAX5 transcriptional activity and im-
pair the formation of PML-NBs (Kurahashi et al. 2011).
Furthermore, reduced protein expression of PML has been
reported in non-Hodgkin’s lymphoma (Gurrieri et al. 2004).
A role for PML in lymphoma was further demonstrated using
mouse models of myc-driven B-lymphoma. Loss of one allele
of E6AP, an E3 ligase for PML, restored PML levels and
induced cellular senescence, leading to a significant delay in
Myc-induced lymphagenesis.
Overall, these studies are in agreement with PML’s widely
reported function as a tumour suppressor in a variety of both
haematopoietic and solid tumours (Gamell et al. 2014), how-
ever, chronic myeloid leukaemia (CML) is an exception to
this. CML is a myeloproliferative disorder that, in common
with APL, is characterised by a specific chromosomal
translocation, in this case t(9;22), which gives rise to
the tyrosine kinase BCR-ABL. The translocation originates
in haematopoietic stem cells that can self-renew, proliferate
and differentiate leading to an excessive accumulation of my-
eloid cells. Tyrosine kinase inhibitors (TKIs) target the kinase
activity of BCR-ABL and have transformed the treatment of
CML, however, the persistence of TKI-resistant stem cells
remains one of the major obstacles to eradicating the
disease (Holyoake and Vetrie 2017). Ito et al. (2008)
found that PML was required for the maintenance of both
normal haematopoietic stem cells and leukaemic stem cells
expressing BCR-ABL. Moreover, they reported that low ex-
pression of PML in CML blasts was associated with improved
overall survival. A number of laboratory studies point to the
potential of using ATO in combination with TKIs to target
CML stem cells (Naka et al. 2010) Fig. 2.
TRIM33
TRIM33, also known as transcriptional intermediary factor 1 γ
(TIF1γ), is a nuclear protein that belongs to the C-VI subfamily
of TRIM proteins containing a C-terminal tandem plant
homeodomain (PHD) and bromodomain module. Members of
this subfamily also belong to the TIF1 family, which are involved
in chromatin-mediated transcriptional regulation. The PHD-
bromodomain module interacts with post-translationally modi-
fied histone tails to recruit TRIM33 to chromatin and stimulate its
E3 ligase activity (Agricola et al. 2011). TRIM33 is implicated in
the regulation of many aspects of haematopoiesis and interacts
with key transcriptional regulators of haematopoiesis, such as
PU.1, TAL1 and SMAD4. The importance of TRIM33 in
haematopoiesis was first reported in a zebrafish model demon-
strating that loss of TRIM33 disrupts both embryonic and adult
haematopoiesis and is required for normal erythroid development
(Ransom et al. 2004). Subsequent studies have found that
TRIM33 is involved in the regulation of haematopoietic stem
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cells (HSC), granulomonopoiesis and macrophage differentia-
tion, transcriptional elongation of erythroid genes (Bai et al.
2010, 2013) and plays a key role in the recruitment of myeloid
cells to sites of inflammation (Demy et al. 2017). It is therefore
not surprising that TRIM33 has also been found to be dysregu-
lated in a number of haematological malignancies. While
TRIM33 is largely considered to exhibit tumour suppressor ac-
tivity, it is also reported to act as oncogene depending on the cell
type involved.
TRIM33 in chronic myelomonocytic leukaemia
Chronic myelomonocytic leukaemia (CMML) is a clonal
HSC malignancy characterised by the expansion of the
granulo-monocytic compartment in the bone marrow,
peripheral blood and spleen. CMML is generally associated
with advancing age and has a median age at diagnosis of 70
(Padron et al. 2015). Using a conditional knockout model,
Aucagne et al. (2011) demonstrated that loss of TRIM33 in
mouse HSCs favoured the expansion of granulo-monocytic
progenitors and older TRIM33-deficient mice exhibited fea-
tures of CMML. Furthermore, they demonstrated that
TRIM33 was downregulated in 35% of CMML patients.
Low levels of TRIM33 in CMML patients were due to hyper-
methylation of the gene promoter and expression could be
restored using the hypomethylating agent decitabine. The
hypomethylating agents azacitidine and decitabine are com-
monly used to treat older patients with CMML (Alfonso et al.
2017) and have recently been shown to confer a significant
survival advantage to CMML patients in the first year after
Fig. 2 TRIM19/PML exerts cell type dependent effects on blood
cancers. In acute promyelocytic leukaemia (APL), B cell acute
lymphoblastic leukaemia (B-ALL) and non-Hodgkin’s lymphoma
(NHL), the tumour suppressive activity of PML is lost. The majority of
patients with APL harbour the t(15;17) translocation resulting in a
promyelocytic leukaemia – retinoic acid receptor α (PML-RARα) gene
and protein. This disrupts the normal function of both proteins leading to
impaired PML-nuclear bodies (PML-NB) formation and a block in
differentiation. In some cases of B-ALL, PML is found translocated to
the transcription factor paired box 5 (PAX5), again disrupting the forma-
tion of PML-NB and leading to decreased differentiation. In NHL re-
duced protein expression of PML is seen due to increased E6AP-
mediated proteasomal degradation of PML. Conversely, PML is seen to
play an oncogenic role in chronic myeloid leukaemia (CML), where it has
been found to be important for self-renewal and quiescence in leukaemic
stem cells
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diagnosis (Zeidan et al. 2017). Future studies are warranted to
investigate whether TRIM33 could be used as a biomarker of
response to these agents in CMML.
TRIM33 in B-cell acute lymphoblastic leukaemia
In contrast to the role of TRIM33 as a tumour suppressor in
CMML, Wang et al. (2015) found that TRIM33 acts as an
oncogene in B-cell acute lymphoblastic leukaemia (B-ALL),
a malignancy of immature B-cells that predominantly affects
young children. TRIM33was identified during an RNAi screen
for essential chromatin regulators in B-ALL. In murine B-ALL
cells, it was demonstrated that TRIM33 is recruited by PU.1 to
select lineage-specific enhancers and inhibits apoptosis in these
cells by blocking activation of the pro-apoptotic gene Bim.
TRIM33-deficient mice displayed selective loss of CD19 and
B220 B lymphoid cells suggesting that TRIM33 is also re-
quired for normal B cell development. While the authors pro-
pose that TRIM33 is essential for the survival of all B cell
neoplasms, there is conflicting evidence to suggest that
TRIM33 has opposing effects in Multiple Myeloma (MM).
MM is characterised by the clonal proliferation of plasma cells,
which are terminally differentiated B cells. TRIM33 is located
on chromosome 1p13.1, a common deleted region seen in MM
patients (Li et al. 2016). Low expression of TRIM33 inMMhas
previously been found to be significantly associated with poor
clinical outcome (Shaughnessy et al. 2007). In concert with this,
we have recently proposed that TRIM33 acts as a tumour sup-
pressor in MM (Johnston et al. 2017 and unpublished
observations). There are well recognised functional and tran-
scriptional differences that distinguish B cells frommore differ-
entiated antibody secreting plasma cells and this may account
for the opposing roles of TRIM33 suggested in B-ALL versus
MM cells (Recaldin and Fear 2016; Nutt et al. 2015) Fig. 3.
TRIM24
TRIM24, also known as TIF1α, is also a member the C-VI
subfamily of TRIM proteins and the TIF1 family. In common
with TRIM33, TRIM24 is involved in chromatin-dependent reg-
ulation of transcription, however, they differ in their specificity
for histone modifications (Herquel et al. 2011a, b). TRIM24
regulates cellular transcription by interacting with nuclear recep-
tors such as retinoic acid and is also involved in controlling the
stability of the tumour suppressor p53. Like many other TRIM
proteins, TRIM24 has been reported to exhibit both tumour
suppressor and oncogenic properties in a cell type dependent
context. Due to its interactions with retinoic acid receptors, it
has been postulated that TRIM24 may play a role in myeloid
differentiation. While there is no direct evidence for this,
dysregulated expression of TRIM24 has been reported in
Fig. 3 The dual role of TRIM33 in the regulation of blood
cancers. In chronic myelomonocytic leukaemia (CMML)
TRIM33 is epigenetically silenced through increased methylation
of its promoter in approximately a third of patients, leading to
loss of tumour suppressor activity. Conversely, TRIM33 has been found
to be essential for the survival of B cell acute lymphoblastic leukaemia
(B-ALL) cells by blocking enhancer mediated activation of the pro-
apoptotic gene BIM
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AML. Gandini et al. (2002) found higher expression of TRIM24
in some subtypes of AML and they report significantly
overexpressed TRIM24 in AML that has transformed from a
pre-leukaemic haematological disorder known as
myelodysplastic syndrome (MDS) but not in untransformed
MDS. TRIM24 has also been implicated in recurrent chromo-
somal rearrangements associated with a neoplasm known as
8p11 myeloproliferative syndrome or EMS (Belloni et al.
2005). This is a raremyeloproliferative neoplasm associatedwith
translocation of Fibroblast Growth Factor Receptor 1 (FGFR1)
on chromosome 8p11 to one of at least 14 partner genes,
resulting in constitutive tyrosine kinase activity (Jackson et al.
2010). EMS is characterized by eosinophilia, T-cell proliferation
and frequent progression to AML (Patnaik et al. 2010).
TRIM13
TRIM13, also known as ret finger protein 2 (RFP2), belongs
to the C-XI subfamily containing a RING finger, one B-box
domain, a coiled-coil domain and a C-terminal transmem-
brane domain. It localises to endoplasmic reticulum (ER)
membranes via its transmembrane domain and regulates the
turnover of ER-associated degradation (ERAD) substrates.
TRIM13 was initially identified as a putative tumour suppres-
sor gene in B cell chronic lymphocytic leukaemia (B-CLL)
(Kapanadze et al. 2000). It is located on chromosome 13 with-
in a minimum commonly deleted region (13q14) that is fre-
quently deleted in CLL and also lost in other B cell malignan-
cies such as MM, mantle cell lymphoma (MCL) and diffuse
large B cell lymphoma (DLBCL). While TRIM13 was first
identified as a candidate tumour suppressor in B-CLL, there
are conflicting reports on its relevance. Following initial iden-
tification, a number of studies have excluded TRIM13 as a
tumour suppressor gene in B-CLL (Rondeau et al. 1999;
Bullrich et al. 2001). However, Baranova et al. (2003) subse-
quently reported downregulated expression of TRIM13 in
CLL patients at advanced stage of disease in comparison to
expression at diagnosis, suggesting that it does exhibit prop-
erties of a tumour suppressor. In MM, deletion of chromo-
some 13q, particularly 13q14, is present in approximately half
of patients at diagnosis and is associated with a poor clinical
outcome. Gatt et al. (2013) investigated the role of TRIM13 in
the pathogenesis of MM using a loss-of-function approach.
Unexpectedly they found that TRIM13 downregulation led
to decreased survival and proliferation ofMM cell lines, along
with inhibition of the NFκB pathway and proteasome activity.
Concluding remarks
As described in this review, TRIM proteins can positively
or negatively regulate the initiation or progression of
blood cancers by affecting processes such as transcrip-
tional regulation, cell cycle control, differentiation and
apoptosis. In fact, many of the TRIM proteins described
can exhibit a dual role either as an oncogene or tumour
suppressor, depending on the context. For example, loss
of the normal function of TRIM19/PML through translo-
cation or E6AP-mediated degradation is implicated in the
pathogenesis of APL, B-ALL and lymphoma, whereas in
CML low TRIM19 expression correlates with improved
overall survival. This demonstrates that the role of TRIM
proteins in the regulation of both normal haematopoiesis
and leukaemogenesis is complex and often cell type spe-
cific, highlighting the need to investigate the biological
relevance of individual TRIMs in the appropriate cell
type. To add a further layer of complexity, a number of
TRIM proteins are known to heterodimerise with other
TRIMs, which is thought to enhance their E3 ligase ac-
tivity or diversify substrate specificity. Two TRIMs,
TRIM24 and TRIM33, described in isolation in this re-
view are known to form a complex that co-operatively
acts in tumour suppression in hepatocellular cancer cells
(Herquel et al. 2011b). Investigation of the role of this hetero-
dimer in relevant blood cancers could reveal additional roles
in the promotion or prevention of oncogenesis. Over half of
TRIM family members, including those discussed here, have
been shown to play an important role in regulating the innate
immune response. The immune system is known to be in-
volved in shaping the evolution and biology of blood cancers
and as our understanding of the role of TRIM proteins in
immunity increases, there may be more TRIMs identified that
indirectly participate in tumour development and progression.
Given their involvement in a variety of diseases, TRIM pro-
teins represent attractive therapeutic targets. The ubiquitin
proteasome system is already established as an impor-
tant therapeutic target in blood cancers. Inhibition of
proteasome activity with bortezomib or carfilzomib is wide-
ly used in all aspects of anti-MM therapies (Landgren and
Iskander 2017). Furthermore, there is increasing interest in
targeting individual E3 ligases either through inhibiting or
altering E3 ligase activity The successful use of ATO to treat
APL represents the first use of a TRIM-specific targeted ther-
apy. As our knowledge of the role of TRIM family members
in blood cancers increases, it is likely that further opportunities
for the development of targeted therapies will emerge.
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